scholarly journals Distinctive vasculopathy with systemic involvement due to levamisole long-term therapy: a case report

2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Bilal Aoun ◽  
Mohammad Alali ◽  
Jad A. Degheili ◽  
Sami Sanjad ◽  
Claudine Vaquin ◽  
...  
Keyword(s):  
Case Report ◽  
Term Therapy ◽  
Systemic Involvement ◽  
Long Term Therapy

Good response to long-term therapy with growth hormone in a patient with 9p trisomy syndrome: A case report and review of the literature

2015 ◽  
Vol 170 (4) ◽  
pp. 1046-1049 ◽  
Author(s):  
Ana Pinheiro Machado Canton ◽  
Mirian Yumie Nishi ◽  
Tatiane Katsue Furuya ◽  
Rosimeire Aparecida Roela ◽  
Alexander Augusto Lima Jorge
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Term Therapy ◽  
Review Of The Literature ◽  
Long Term Therapy

scholarly journals Complete resolution of primary sclerosing peritonitis ("abdominal cocoon") following long term therapy for Tropheryma whipplei: a case report and review of literature

2009 ◽  
Vol 2009 (jun25 1) ◽  
pp. bcr0420091810-bcr0420091810 ◽  
Author(s):  
R. Tarquini ◽  
S. Colagrande ◽  
M. Rosselli ◽  
M. Novelli ◽  
S. Dolenti ◽  
...  
Keyword(s):  
Case Report ◽  
Complete Resolution ◽  
Tropheryma Whipplei ◽  
Term Therapy ◽  
Review Of Literature ◽  
Abdominal Cocoon ◽  
Sclerosing Peritonitis ◽  
Long Term Therapy

Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature

2020 ◽  
Vol 31 (7) ◽  
pp. 754-757
Author(s):  
Olga Nigro ◽  
Andrea Coppola ◽  
Tiziana Tartaro ◽  
Alessandro Tuzi ◽  
Ilaria Vallini ◽  
...  
Keyword(s):  
Case Report ◽  
Young Patient ◽  
Term Therapy ◽  
Review Of The Literature ◽  
Continue Treatment ◽  
Long Term Therapy

Hematogenous osteomyelitis of the calcaneus

1993 ◽  
Vol 83 (12) ◽  
pp. 681-684 ◽  
Author(s):  
IM Fox ◽  
JM Aponte
Keyword(s):  
Case Report ◽  
Surgical Decompression ◽  
Term Therapy ◽  
Oral Antibiotics ◽  
Hematogenous Osteomyelitis ◽  
Long Term Therapy ◽  
Delay In Treatment

A case report of hematogenous calcaneal osteomyelitis has been presented along with a brief review. Hematogenous osteomyelitis of the foot is an uncommon but potentially devastating disease that can result in severe long-term sequelae. An index of suspicion in cases such as these can help the physician prevent unnecessary delay in treatment. In pediatric hematogenous osteomyelitis, oral antibiotics can often be sufficient for long-term therapy, provided sufficient surgical decompression is performed.

Long-term therapy with miglustat and cognitive decline in the adult form of Niemann-Pick disease type C: a case report

2018 ◽  
Vol 39 (6) ◽  
pp. 1015-1019 ◽  
Author(s):  
Stefano Tozza ◽  
Raffaele Dubbioso ◽  
Rosa Iodice ◽  
Antonietta Topa ◽  
Marcello Esposito ◽  
...  
Keyword(s):  
Case Report ◽  
Cognitive Decline ◽  
Disease Type ◽  
Term Therapy ◽  
Niemann Pick Disease ◽  
Type C ◽  
Niemann Pick ◽  
Long Term Therapy ◽  
Pick Disease

scholarly journals Long-Term Therapy of a Patient with Summerskill-Walshe-Tygstrup Syndrome by Applying Prometheus® Liver Dialysis: A Case Report

2012 ◽  
Vol 6 (2) ◽  
pp. 550-556 ◽  
Author(s):  
Mikolaj Walensi ◽  
Ali Canbay ◽  
Oliver Witzke ◽  
Guido Gerken ◽  
Alisan Kahraman
Keyword(s):  
Case Report ◽  
Term Therapy ◽  
Long Term Therapy

scholarly journals Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Fereidoun Azizi ◽  
Atieh Amouzegar ◽  
Hengameh Abdi
Keyword(s):  
Case Report ◽  
Low Dose ◽  
Normal Serum ◽  
Term Therapy ◽  
Graves Disease ◽  
Major Drawback ◽  
Multiple Recurrences ◽  
Long Term Therapy ◽  
Multiple Relapses

Abstract Introduction Methimazole (MMI) is the treatment of choice for patients with Graves’ disease. The major drawback of this treatment is the relapse of hyperthyroidism in half of the patients after discontinuation of the recommended conventional 12–18 months of MMI treatment. TSH receptor antibody (TRAb) concentration is recognized as the strongest predictor of hyperthyroidism relapse. In this case report, efficacy of low-dose MMI to control hyperthyroidism even after multiple recurrences in the setting of normal TRAb concentrations is shown. Case presentation An 80-year-old Iranian woman with Graves’ disease was treated with MMI for 31 years. While receiving treatment, she always had a normal serum TRAb concentration; however, three times during the 31 years she decided to stop MMI therapy, and each time the disease recurred 16–21 months after MMI withdrawal. It is noteworthy that she maintained euthyroidism with the low-dose 1.25–2.5 mg MMI daily without any adverse events during three decades of treatment. Conclusions Normal serum TRAb is not a sufficiently strong marker to predict relapse of Graves’ hyperthyroidism. Long-term therapy with low-dose MMI is an effective and safe treatment to sustain euthyroidism.

Sign in / Sign up

Export Citation Format

Share Document